Among them, HER2 has gained particular interest, because HER2 overexpression is present in approximately 20% of invasive breast cancer cases and renders these tumors responsive to treatment with the monoclonal antibody trastuzumab (Herceptin®). Here, ERBB2 is linked to invasive breast carcinoma.